Congestive heart failure is a rare event in patients receiving imatinib therapy

Ehab Atallah, Jean Bernard Durand, Hagop Kantarjian, Jorge Cortes

Research output: Contribution to journalArticle

Abstract

A recent preclinical study suggested that imatinib may be cardiotoxic in some patients. We reviewed all reported serious adverse events of cardiac adverse events occurring in patients on clinical trials involving imatinib. Among 1276 patients enrolled, 22 (1.7%) were identified as having symptoms that could be attributed to systolic heart failure. The median age was 70 years (range, 49 to 83 years). The median time from start of imatinib therapy was 162 days (range, 2-2045 days). At the time these events were reported, 8 (0.6%) were considered possibly or probably related to imatinib. A total of 18 patients had previous medical conditions predisposing to cardiac failure: congestive heart failure (CHF; 6 [27%] patients), diabetes mellitus (6 [27%] patients), hypertension (10 [45%] patients), coronary artery disease (CAD; 8 [36%] patients), arrhythmia (3 [14%] patients), and cardiomyopathy (1 [5%] patient). Of the 22 patients, 11 continued imatinib therapy with dose adjustments and management for the CHF symptoms without further complications. Imatinib therapy as a causal factor of CHF is uncommon, mainly seen in elderly patients with preexisting cardiac conditions. Patients with previous cardiac history should be monitored closely and treated aggressively with standard medical therapy, including diuretics, if they develop symptoms suggestive of heart failure.

Original languageEnglish (US)
Pages (from-to)1233-1237
Number of pages5
JournalBlood
Volume110
Issue number4
DOIs
StatePublished - Aug 15 2007
Externally publishedYes

Fingerprint

Heart Failure
Therapeutics
Medical problems
Diuretics
Imatinib Mesylate
Computer aided design
Systolic Heart Failure
Preexisting Condition Coverage
Cardiomyopathies
Cardiac Arrhythmias
Coronary Artery Disease
Diabetes Mellitus
History
Clinical Trials
Hypertension

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Congestive heart failure is a rare event in patients receiving imatinib therapy. / Atallah, Ehab; Durand, Jean Bernard; Kantarjian, Hagop; Cortes, Jorge.

In: Blood, Vol. 110, No. 4, 15.08.2007, p. 1233-1237.

Research output: Contribution to journalArticle

Atallah, Ehab ; Durand, Jean Bernard ; Kantarjian, Hagop ; Cortes, Jorge. / Congestive heart failure is a rare event in patients receiving imatinib therapy. In: Blood. 2007 ; Vol. 110, No. 4. pp. 1233-1237.
@article{01b84ec5318949f3bea504bff4d70527,
title = "Congestive heart failure is a rare event in patients receiving imatinib therapy",
abstract = "A recent preclinical study suggested that imatinib may be cardiotoxic in some patients. We reviewed all reported serious adverse events of cardiac adverse events occurring in patients on clinical trials involving imatinib. Among 1276 patients enrolled, 22 (1.7{\%}) were identified as having symptoms that could be attributed to systolic heart failure. The median age was 70 years (range, 49 to 83 years). The median time from start of imatinib therapy was 162 days (range, 2-2045 days). At the time these events were reported, 8 (0.6{\%}) were considered possibly or probably related to imatinib. A total of 18 patients had previous medical conditions predisposing to cardiac failure: congestive heart failure (CHF; 6 [27{\%}] patients), diabetes mellitus (6 [27{\%}] patients), hypertension (10 [45{\%}] patients), coronary artery disease (CAD; 8 [36{\%}] patients), arrhythmia (3 [14{\%}] patients), and cardiomyopathy (1 [5{\%}] patient). Of the 22 patients, 11 continued imatinib therapy with dose adjustments and management for the CHF symptoms without further complications. Imatinib therapy as a causal factor of CHF is uncommon, mainly seen in elderly patients with preexisting cardiac conditions. Patients with previous cardiac history should be monitored closely and treated aggressively with standard medical therapy, including diuretics, if they develop symptoms suggestive of heart failure.",
author = "Ehab Atallah and Durand, {Jean Bernard} and Hagop Kantarjian and Jorge Cortes",
year = "2007",
month = "8",
day = "15",
doi = "10.1182/blood-2007-01-070144",
language = "English (US)",
volume = "110",
pages = "1233--1237",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "4",

}

TY - JOUR

T1 - Congestive heart failure is a rare event in patients receiving imatinib therapy

AU - Atallah, Ehab

AU - Durand, Jean Bernard

AU - Kantarjian, Hagop

AU - Cortes, Jorge

PY - 2007/8/15

Y1 - 2007/8/15

N2 - A recent preclinical study suggested that imatinib may be cardiotoxic in some patients. We reviewed all reported serious adverse events of cardiac adverse events occurring in patients on clinical trials involving imatinib. Among 1276 patients enrolled, 22 (1.7%) were identified as having symptoms that could be attributed to systolic heart failure. The median age was 70 years (range, 49 to 83 years). The median time from start of imatinib therapy was 162 days (range, 2-2045 days). At the time these events were reported, 8 (0.6%) were considered possibly or probably related to imatinib. A total of 18 patients had previous medical conditions predisposing to cardiac failure: congestive heart failure (CHF; 6 [27%] patients), diabetes mellitus (6 [27%] patients), hypertension (10 [45%] patients), coronary artery disease (CAD; 8 [36%] patients), arrhythmia (3 [14%] patients), and cardiomyopathy (1 [5%] patient). Of the 22 patients, 11 continued imatinib therapy with dose adjustments and management for the CHF symptoms without further complications. Imatinib therapy as a causal factor of CHF is uncommon, mainly seen in elderly patients with preexisting cardiac conditions. Patients with previous cardiac history should be monitored closely and treated aggressively with standard medical therapy, including diuretics, if they develop symptoms suggestive of heart failure.

AB - A recent preclinical study suggested that imatinib may be cardiotoxic in some patients. We reviewed all reported serious adverse events of cardiac adverse events occurring in patients on clinical trials involving imatinib. Among 1276 patients enrolled, 22 (1.7%) were identified as having symptoms that could be attributed to systolic heart failure. The median age was 70 years (range, 49 to 83 years). The median time from start of imatinib therapy was 162 days (range, 2-2045 days). At the time these events were reported, 8 (0.6%) were considered possibly or probably related to imatinib. A total of 18 patients had previous medical conditions predisposing to cardiac failure: congestive heart failure (CHF; 6 [27%] patients), diabetes mellitus (6 [27%] patients), hypertension (10 [45%] patients), coronary artery disease (CAD; 8 [36%] patients), arrhythmia (3 [14%] patients), and cardiomyopathy (1 [5%] patient). Of the 22 patients, 11 continued imatinib therapy with dose adjustments and management for the CHF symptoms without further complications. Imatinib therapy as a causal factor of CHF is uncommon, mainly seen in elderly patients with preexisting cardiac conditions. Patients with previous cardiac history should be monitored closely and treated aggressively with standard medical therapy, including diuretics, if they develop symptoms suggestive of heart failure.

UR - http://www.scopus.com/inward/record.url?scp=34548030470&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548030470&partnerID=8YFLogxK

U2 - 10.1182/blood-2007-01-070144

DO - 10.1182/blood-2007-01-070144

M3 - Article

C2 - 17449798

AN - SCOPUS:34548030470

VL - 110

SP - 1233

EP - 1237

JO - Blood

JF - Blood

SN - 0006-4971

IS - 4

ER -